Coya Therapeutics, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report. Coya is a clinical-stage biotechnology company developing therapies intended to enhance regulatory T-cell function; it has no products approved for sale.
Financial performance and liquidity
| Metric | 2023 | 2022 |
|---|---|---|
| Collaboration revenue | $6.0 million | None |
| Research and development expense | $5.5 million | $4.4 million |
| General and administrative expense | $7.8 million | $4.8 million |
| Total operating expenses | $13.9 million | $9.8 million |
| Operating loss | $7.9 million | $9.8 million |
| Net loss | $8.0 million | $12.2 million |
| Net loss per share, basic and diluted | $0.79 | $4.73 |
| Cash used in operating activities | $11.2 million | $7.2 million |
| Cash and cash equivalents at year-end | $32.6 million | $5.9 million |
The $6.0 million of collaboration revenue arose from the Dr. Reddy’s agreement and is not product-sale revenue. The company allocated $6.0 million of the $7.5 million upfront payment to the license and recognized it in 2023; the remaining $1.5 million was deferred for research and development services. The $7.5 million payment was received in January 2024 and was a receivable at year-end.
At December 31, 2023, total current assets were $41.2 million and current liabilities were $5.1 million. The company reported no convertible promissory notes outstanding, compared with $13.0 million at year-end 2022; the notes converted to common stock at the January 2023 IPO. There is no meaningful product gross margin to report because Coya had no product sales.
Financing activities provided $38.4 million in 2023, including $24.1 million net proceeds from the December private placement and $14.3 million net IPO proceeds. Cash increased by $26.7 million during the year. Management expects year-end cash, together with the January 2024 upfront payment, to fund operations and capital requirements into 2026; it cautions that estimates depend on assumptions and cash could be used sooner.
Material changes versus 2022
- Revenue rose from zero to $6.0 million, reflecting the Dr. Reddy’s collaboration.
- Net loss narrowed by $4.3 million, principally because of collaboration revenue, the absence of the prior-year $2.5 million fair-value loss on convertible notes, and higher other income. This was partly offset by increased operating costs and $0.7 million of income tax expense.
- Operating expenses increased $4.1 million. R&D rose $1.1 million, with increased preclinical and internal spending partly offset by lower Houston Methodist research and clinical-candidate costs. G&A rose $3.0 million, mainly due to personnel and professional fees.
- Cash increased substantially following the IPO and private placement. Common shares outstanding rose to 14.4 million from 2.6 million at year-end 2022; the December placement issued 4.37 million shares.
Outlook, development, and key risks
- COYA 302: The company planned to file an ALS IND in the first half of 2024 and begin a Phase 2 trial following FDA acceptance. It also announced plans to pursue frontotemporal dementia, Parkinson’s disease, and Alzheimer’s disease indications, with an FTD IND targeted before year-end 2024 and Parkinson’s animal studies planned for 2024. These are forward-looking plans, not achieved milestones.
- COYA 301 and Alzheimer’s study: A 38-patient, randomized, placebo-controlled Phase 2 study of low-dose IL-2 was fully enrolled; top-line data were anticipated in Q3 2024.
- Early data caveat: COYA 302’s ALS proof-of-concept study involved four patients and was open-label; COYA 301’s Alzheimer’s proof-of-concept study involved eight patients and was open-label. Results are preliminary and do not establish efficacy. The filing reports no serious adverse events in these small studies.
- Other pipeline: COYA 201’s lupus-nephritis animal study did not meet its primary endpoint, and six of 12 animals died at the highest dose tested. The company is evaluating the findings and potential indications. COYA 101 completed Phase 1 and Phase 2a ALS studies, but management said it was prioritizing other candidates.
- Dr. Reddy’s collaboration: Dr. Reddy’s received exclusive COYA 302 commercialization rights for ALS in the United States, Canada, the EU, and UK, alongside previously granted rights in certain other territories. Coya retains responsibility for clinical development and U.S. ALS regulatory approval. The agreement includes $4.2 million payments upon FDA IND acceptance and first Phase 2 patient dosing, up to $40 million in development milestones and up to approximately $677 million in sales milestones for the new territories, plus low-to-mid-teens royalties before Coya’s own license royalties. Milestones are contingent and not assured; a commercial supply agreement had not yet been signed at filing.
- Funding and execution: Coya expects continued losses and higher R&D spending in 2024, particularly for COYA 301 and COYA 302, and may need substantial additional capital. Failure to obtain financing could force delays, reductions, or discontinuation of programs. Development, regulatory, manufacturing, enrollment, intellectual-property, and third-party collaboration risks are significant.
- Other items: The audited financial statements received an unqualified opinion. Management reported effective disclosure controls and internal control over financial reporting as of year-end; the auditor was not engaged to audit internal controls. No material pending litigation was reported.
Important facts for investors to verify
- Whether the COYA 302 ALS IND was accepted and whether the Phase 2 trial started on the stated timeline; review the protocol, enrollment, and subsequent clinical updates.
- Whether the 38-patient Alzheimer’s study reported data as anticipated, and how results compare with the preliminary open-label findings.
- Current cash, operating burn, and runway against management’s “into 2026” estimate, including the timing and use of the $7.5 million upfront payment.
- Actual receipt and conditions for the two $4.2 million Dr. Reddy’s development payments, and progress on a commercial supply agreement and remaining license obligations.
- Whether the small, uncontrolled proof-of-concept results are replicated in adequately powered, controlled trials, and whether COYA 201’s high-dose animal toxicity affects development plans.